Recent News

• 03.26.2026 - Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735
• 03.05.2026 - Viking Therapeutics to Participate at Upcoming Investor Conferences
• 02.11.2026 - Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
• 02.04.2026 - Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026
• 01.12.2026 - Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
• 01.08.2026 - Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
• 01.07.2026 - Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer
• 01.05.2026 - Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Recent Filings

• 03.27.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.10.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.11.2026 - 8-K Current report
• 02.11.2026 - EX-99.1 EX-99.1
• 02.11.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 01.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.26.2026 - 3 Initial statement of beneficial ownership of securities
• 01.05.2026 - 144 Report of proposed sale of securities
• 01.05.2026 - 144 Report of proposed sale of securities
• 01.05.2026 - 4 Statement of changes in beneficial ownership of securities